Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities

Barry V. Fortner, Kurt Tauer, Ling Zhu, Theodore A. Okon, Kelley Moore, Davis Templeton, Lee Schwartzberg

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. Methods: We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. Results: The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. Conclusions: This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.

Original languageEnglish (US)
Article number22
JournalBMC Cancer
Volume4
DOIs
StatePublished - May 20 2004

Fingerprint

Neutropenia
Drug Therapy
Ambulatory Care
Therapeutics
Colony-Stimulating Factors
Surveys and Questionnaires
Appointments and Schedules
Hospitalization
Economics
Physicians
Filgrastim
pegfilgrastim
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Medical visits for chemotherapy and chemotherapy-induced neutropenia : A survey of the impact on patient time and activities. / Fortner, Barry V.; Tauer, Kurt; Zhu, Ling; Okon, Theodore A.; Moore, Kelley; Templeton, Davis; Schwartzberg, Lee.

In: BMC Cancer, Vol. 4, 22, 20.05.2004.

Research output: Contribution to journalArticle

Fortner, Barry V. ; Tauer, Kurt ; Zhu, Ling ; Okon, Theodore A. ; Moore, Kelley ; Templeton, Davis ; Schwartzberg, Lee. / Medical visits for chemotherapy and chemotherapy-induced neutropenia : A survey of the impact on patient time and activities. In: BMC Cancer. 2004 ; Vol. 4.
@article{85f09120083742a2a133a8111d8c4338,
title = "Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities",
abstract = "Background: Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. Methods: We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. Results: The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. Conclusions: This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.",
author = "Fortner, {Barry V.} and Kurt Tauer and Ling Zhu and Okon, {Theodore A.} and Kelley Moore and Davis Templeton and Lee Schwartzberg",
year = "2004",
month = "5",
day = "20",
doi = "10.1186/1471-2407-4-22",
language = "English (US)",
volume = "4",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Medical visits for chemotherapy and chemotherapy-induced neutropenia

T2 - A survey of the impact on patient time and activities

AU - Fortner, Barry V.

AU - Tauer, Kurt

AU - Zhu, Ling

AU - Okon, Theodore A.

AU - Moore, Kelley

AU - Templeton, Davis

AU - Schwartzberg, Lee

PY - 2004/5/20

Y1 - 2004/5/20

N2 - Background: Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. Methods: We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. Results: The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. Conclusions: This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.

AB - Background: Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. Methods: We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. Results: The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. Conclusions: This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=3042718940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042718940&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-4-22

DO - 10.1186/1471-2407-4-22

M3 - Article

C2 - 15153249

AN - SCOPUS:3042718940

VL - 4

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 22

ER -